哪些患者应该接种带状疱疹疫苗？
Which patients should receive the herpes zoster vaccine?
作者信息
Short Mandy D, Fergus Christina
机构信息
Mandy D. Short and Christina Fergus are pharmacists at Blue Cross Blue Shield of Arizona. The authors have disclosed no potential conflicts of interest, financial or otherwise.
出版信息
JAAPA. 2019 Sep;32(9):18-20. doi: 10.1097/01.JAA.0000578788.69674.2b.
The recombinant adjuvanted zoster vaccine (RZV, trade name Shingrix) is preferentially recommended by the Advisory Committee on Immunization Practices to prevent herpes zoster and related complications in immunocompetent adults age 50 years and older. This article reviews efficacy and safety of the vaccine, its use in special populations, and how to prevent administration errors to answer the question "Which patients should receive the herpes zoster vaccine?"
重组佐剂带状疱疹疫苗（RZV，商品名欣安立适）被免疫实践咨询委员会优先推荐用于预防50岁及以上免疫功能正常成年人的带状疱疹及相关并发症。本文回顾了该疫苗的有效性和安全性、其在特殊人群中的使用情况，以及如何预防接种错误，以回答“哪些患者应接种带状疱疹疫苗？”这一问题。
Zotero 插件